Rationale for Using Cryocompression to Prevent Chemo-Induced Neuropathy

Video

Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.

Mary Katherine Montes de Oca, MD, spoke with CancerNetwork® in an interview at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer about the mechanism of action for cryocompression as an intervention for preventing peripheral neuropathy associated with chemotherapy for patients with gynecologic cancers.

Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, indicated that cryocompression is a treatment that combines 2 strategies: compression therapy and cryotherapy on the patients’ hands and feet. By inducing vasoconstriction through this process, Montes de Oca states that cryocompression may reduce the likelihood of cytotoxic agents reaching the hands and feet that may cause neuropathy.

Data from a self-controlled trial indicated that patients who underwent cryocompression less frequently experienced moderate to severe symptoms of neuropathy compared with those who did not receive the intervention. At baseline, neuropathy symptoms were identified in 2.2% of cases where cryocompression was not used compared with 3.3% where it was used. At final assessment, the rate of neuropathy symptoms was 13.2% and 7.7% in each respective group.

Transcript:

Cryocompression is a combination of cold therapy and compression therapy on the hands and feet. The proposed mechanism is that the cold therapy and the compression therapy cause vasoconstriction, which then leads to decreased blood circulation to the hands and the feet, and then decreased delivery of chemotherapy or neurotoxic agents that cause neuropathy to the hands and feet.

There are a few options for the prevention of neuropathy. There are some medications that can be used for treatment once a patient is diagnosed with neuropathy. But for prevention, the only other intervention that has really shown promise is cryotherapy—just the cold therapy without the compression therapy. The goal of this study was to look at the two combined.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content